Cytosolic mRNA Target and Bioavailability of Nanoparticulate siRNA delivery systems for gene silencing.

Cytosolic mRNA Target and Bioavailability of Nanoparticulate siRNA delivery systems for gene silencing. Curr Drug Targets. 2016 Jun 19; Authors: Abstract Recent research in medical and pharmaceutical sciences has benefited from advances in molecular biology and genetics, which made possible a diagnosis at the molecular level in more and more diseases. This implies the drug treatment at the molecular level. The interest in Ribonucleic acid interference (RNAi) is based on the mechanism operates by eliminating the messenger RNAs (mRNAs) coding for multiple proteins, which open solutions for treating many types of diseases. Small (short) interfering RNA (siRNA) has quickly been established as an effective gene-silencing strategy in animal models, and more recently in human clinical trials, as a potential therapeutic approach. Various nanoparticulate drug delivery systems for siRNA delivery have been explored extensively. However, there are many more barriers and challenges that need to be addressed and overcome to achieve the ideal formulation in terms of selectivity, efficacy and safety. One of the major causes of the drawback of these treatments is the difficulty to transport the nucleic acids in the cytosol and organelles. These delivery systems will favorably alter the pharmacokinetics and biodistribution of siRNAs, should be biocompatible and genocompatible to avoid immune stimulation and off-target gene effects. These properties ar...
Source: Current Drug Targets - Category: Drugs & Pharmacology Tags: Curr Drug Targets Source Type: research